Clinical Trials Logo
  1. Home
  2. Other
  3. NCT06111846

Study of Human Bone Marrow Mesenchymal Stem Cells in aPAP

Autoimmune Pulmonary Alveolar Proteinosis Clinical Trial

Official title:
An Open-label Phase IIa Study to Evaluate the Safety and Preliminary Efficacy of hBMMSC Injection in the Treatment of aPAP

Clinical Trial Summary

The purpose of this open-label phase IIa clinical trial study is to evaluate the safety and preliminary efficacy of hBMMSC intravenous treatment in patients with aPAP.

Clinical Trial Description

Autoimmune pulmonary alveolar proteinosis (aPAP) is a rare lung disease for which there is no specific drug treatment. Currently, the standard treatment strategy for PAP is whole-lung lavage (WLL), which is invasive and has limited therapeutic efficacy. The purpose of this study is to evaluate the safety and preliminary efficacy of hBMMSC intravenous treatment in patients with aPAP. The clinical trial intends to involve 10 participants. The trial is expected to last approximately 2 years. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06111846
Study type Interventional
Source Jiuzhitang Maker (Beijing) Cell Technology Co.,Ltd.
Contact
Status Not yet recruiting
Phase Phase 2
Start date November 1, 2023
Completion date August 30, 2026
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04544293 - Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Phase 3
Completed NCT02702180 - Efficacy and Safety of Inhaled Molgramostim (rhGM-CSF) in Autoimmune Pulmonary Alveolar Proteinosis Phase 2
Completed NCT00901511 - Inhaled GM-CSF Therapy of Autoimmune PAP Phase 2
Completed NCT03006146 - Evaluation of a Single Dose of Inhaled Sargramostim in Patients With Autoimmune Pulmonary Alveolar Proteinosis Phase 1
Not yet recruiting NCT06431776 - Inhaled Molgramostim in Pediatric Participants With Autoimmune Pulmonary Alveolar Proteinosis (aPAP). Phase 3
Recruiting NCT02243228 - Inhalation of Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) for Autoimmune Pulmonary Alveolar Proteinosis (PAP) Phase 2
Completed NCT03231033 - Pioglitazone Therapy of Autoimmune Pulmonary Alveolar Proteinosis Autoimmune Pulmonary Alveolar Proteinosis Phase 1
Completed NCT03531996 - The Longitudinal Evaluation of Autoimmune Pulmonary Alveolar Proteinosis
Completed NCT03482752 - Safety Extension Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis Phase 3